Clinical Trials
54 trialsA Study to Learn About the Study Medicine PF-07985045 When Given Alone or With Other Anti-cancer Therapies in People With Advanced Solid Tumors That Have a Change in a Gene.
Pfizer
PEACH
Royal Marsden NHS Foundation Trust
TASUC-Neo
Brown University
MEDINDUCTION
Gustave Roussy, Cancer Campus, Grand Paris
Phase 1b Safety Study of Xevinapant, Weekly Cisplatin, and RT in Participants With Unresected LA SCCHN (HyperlynX)
EMD Serono
A Study of LY3039478 in Participants With Advanced or Metastatic Solid Tumors
Eli Lilly and Company
A Phase I Clinical Study for Evaluating the Safety and Efficacy of MASCT-I in Patients With Advanced Solid Tumors
HRYZ Biotech Co.
SCope-D1
AstraZeneca
Induction
The Netherlands Cancer Institute
Study to Assess the Effects of GS-3583 in Participants With Advanced Solid Tumors
Gilead Sciences
A Pilot Window-Of-Opportunity Study of the Anti-PD-1 Antibody Pembrolizumab in Patients With Resectable Malignant Pleural Mesothelioma
University of Chicago
Gemcitabine and Cisplatin With Ivosidenib or Pemigatinib for the Treatment of Unresectable or Metastatic Cholangiocarcinoma
Academic and Community Cancer Research United
Testing AZD1775 inC Combination With Radiotherapy and Chemotherapy in Cervical, Upper Vaginal and Uterine Cancers
National Cancer Institute (NCI)
A Dose Escalation Study of Adavosertib(MK1775) in Combination With 5-FU or 5-FU/CDDP in Patients With Advanced Solid Tumor (1775-005
Merck Sharp & Dohme LLC
Neoadjuvant Chemoradiation Plus Pembrolizumab Followed By Consolidation Pembrolizumab in NSCLC
Case Comprehensive Cancer Center
IBI188 Combination Therapy in Solid Tumors
Innovent Biologics (Suzhou) Co. Ltd.
PDR001 in Combination With Platinum-doublet Chemotherapy and Other Immunology Agents in PD-L1 Unselected, Metastatic NSCLC Patients
Novartis
Study of Cytoreductive Surgery and Hyperthermic Intraoperative Chemotherapy With Pemetrexed and Cisplatin for MPM
Baylor College of Medicine
Study to Evaluate the Safety and Tolerability of Andecaliximab as Monotherapy and in Combination With Anti-Cancer Agents in Japanese Participants With Gastric or Gastroesophageal Junction Adenocarcinoma
Gilead Sciences
Phase Ib/II Study of M3814 With Etoposide and Cisplatin in Small Cell Lung Cancer (SCLC) Extensive Disease (ED)
EMD Serono
0805GCC
University of Maryland, Baltimore
A Study of Rovalpituzumab Tesirine (SC16LD6.5) in the Frontline Treatment of Patients With Extensive Stage Small Cell Lung Cancer
AbbVie
Phase Ib Study of Alpelisib With Cisplatin in Patients With HPV+ Solid Tumor Malignancies
University of California, San Francisco
BIBW 2992 as add-on to Gem/Cis in Advanced Biliary Tract Cancer
Johannes Gutenberg University Mainz
A Safety Study in Participants With Advanced Solid Tumors
Eli Lilly and Company
Dasatinib
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
SS1(dsFV)PE38 Plus Pemetrexed and Cisplatin to Treat Malignant Pleural Mesothelioma
National Institutes of Health Clinical Center (CC)
Azacitidine and Cisplatin in Patients With Advanced Lung or Head and Neck Cancer
Loma Linda University
Ficlatuzumab, Cisplatin and IMRT in Locally Advanced Head and Neck Squamous Cell Carcinoma
University of Pittsburgh
IPI Biochemotherapy for Chemonaive Patients With Metastatic Melanoma
M.D. Anderson Cancer Center
Cancer Immunotherapy GSK1572932A as Adjuvant Therapy for Patients With Tumor-antigen-positive Non-Small Cell Lung Cancer
GlaxoSmithKline
Azacitidine and Cisplatin for Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck
University of Kansas Medical Center
Phase I Study of IMRT and Molecular-Image Guided Adaptive Radiation Therapy for Advanced HNSCC
Virginia Commonwealth University
Sym004 in Subjects With Stage IV Non-small Cell Lung Cancer
EMD Serono
Selumetinib (AZD6244, ARRY-142886) J-BTC Phase 1 Study
AstraZeneca
Proton Radiation Therapy With Cisplatin and Etoposide Followed by Surgery in Stage III Non-Small Cell Lung Cancer
Massachusetts General Hospital
Calcitriol, Cisplatin, and Gemcitabine Hydrochloride in Treating Patients With Advanced Solid Tumors That Cannot Be Removed by Surgery
Roswell Park Cancer Institute
Radiation Therapy, Cisplatin, and Etoposide in Treating Patients With Non-small Cell Lung Cancer That Cannot Be Removed by Surgery
University of Washington
HALO
Debiopharm International SA
Determination of Safety, Efficacy, and Pharmacokinetics of "Regorafenib" Combined With Pemetrexed and Cisplatin in Patients With Nonsquamous Non-Small Cell Lung Cancer
Bayer
EMD 1201081 + 5-FU + Cisplatin + Cetuximab in Subjects With Recurrent / Metastatic Squamous Cell Carcinoma of the Head and Neck
Merck KGaA, Darmstadt, Germany
Gefitinib, Cisplatin, Irinotecan, and Radiation Therapy Before Surgery in Treating Patients With Esophageal Cancer or Gastroesophageal Junction Cancer That Can Be Removed By Surgery
University of California, San Francisco
Safety of AMG 706 Plus Panitumumab Plus Gemcitabine-Cisplatin in the Treatment of Patients With Advanced Cancer
Amgen
A Dose Ascending Study of Gemcitabine Elaidate (CO-101) in Combination With Cisplatin
Clovis Oncology, Inc.
A Study of TS-1, Cisplatin (CDDP) and RAD001 (Everolimus)
National University Hospital, Singapore
A Study of Pre-Operative Treatment of Newly-Diagnosed, Surgically-Resectable Osteosarcoma With Doxorubicin, Ifosfamide, Etoposide, and Cisplatin With Early Metabolic Assessment of Response
University of Chicago
Phase Ib Study of Gemcitabine Plus Cisplatin or Carboplatin Plus Dovitinib in Patients With Advanced Solid Tumors
Icahn School of Medicine at Mount Sinai
7-hydroxystaurosporine and Cisplatin in Treating Patients With Advanced Malignant Solid Tumors
National Cancer Institute (NCI)
Veliparib, Cisplatin, and Gemcitabine Hydrochloride in Treating Patients With Advanced Biliary, Pancreatic, Urothelial, or Non-Small Cell Lung Cancer
National Cancer Institute (NCI)
RAD001 With Weekly Cisplatin and Radiation Therapy in Patients With Locally Advanced Head and Neck Cancer
Dana-Farber Cancer Institute